全球大麻素市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計大麻素市場將從 2025 年的 578.5 億美元成長到 2034 年的 3,638.8 億美元，2026 年至 2034 年的複合年成長率為 22.67%。

受監管改革、臨床研究以及消費者對包括CBD在內的大麻素產品日益成長的興趣的推動，全球大麻素市場正在快速擴張。北美和歐洲部分地區將大麻合法化用於醫療用途，為製藥和健康產業鋪平了道路；同時，消費者對局部用藥、膳食補充劑和機能性食品的廣泛接受，也創造了多元化的收入來源。對種植、萃取和配方技術的投資，正在提升產業能力和產品多樣性，從而加速市場成長和商業性認可。

關鍵成長要素包括越來越多的臨床和臨床前證據表明大麻素在疼痛管理、癲癇和其他適應症方面具有潛力，以及多個司法管轄區的放鬆管制創造了商業機會。萃取、純化和均質化技術的進步，以及奈米乳劑和經皮給藥系統等遞送技術的創新，正在提高生物利用度和消費者信心。大型公司的垂直整合和策略併購活動也促進了供應鏈的專業化和整個產業品質標準的提升。

未來前景樂觀，但存在區域差異。如果後期臨床試驗證實療效，藥用級大麻素療法可望佔據高價值市場。同時，隨著劑量標準化和標籤清晰化，消費市場也將日益成熟。隨著大型企業尋求垂直整合的供應鏈，以及監管機構強調品管和可追溯性，預計產業整合將會出現。給藥平台和臨床研究的持續創新將影響治療方法的普及及其長期成長軌跡。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球大麻素市場：依產品類型分類

• 市場分析、洞察與預測
• 大麻二酚
• 四氫大麻酚
• 大麻酚
• 其他

第5章 全球大麻素市場：依應用領域分類

• 市場分析、洞察與預測
• 醫療應用（慢性疼痛管理、神經系統疾病管理、腫瘤學等）
• 非醫療用途

第6章：全球大麻素市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路商店

第7章 全球大麻素市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Mylan NV（Viatris Inc.）
  • Alkem Labs
  • GW Pharmaceuticals Plc（Jazz Pharmaceuticals）
  • Tilray Inc
  • Aurora Cannabis Inc
  • Canopy Growth Corporation
  • The Cronos Group
  • Endoca
  • Cannoid LLC
  • Medical Marijuana Inc

The Cannabinoids Market size is expected to reach USD 363.88 Billion in 2034 from USD 57.85 Billion (2025) growing at a CAGR of 22.67% during 2026-2034.

The global cannabinoids market has expanded rapidly as legal reform, clinical research, and consumer interest in CBD and other cannabinoid products converge. Medical legalization in parts of North America and Europe opened pharmaceutical and wellness channels, while broad consumer adoption of topicals, nutraceuticals, and functional foods created diverse revenue streams. Investment across cultivation, extraction, and formulation technologies increased industrial capacity and product variety, accelerating market growth and commercial visibility.

Key drivers include increasing clinical and preclinical evidence for cannabinoids' potential in pain management, epilepsy, and other indications, plus regulatory loosening in several jurisdictions that create commercial opportunities. Advancements in extraction, purification, and consistent formulation-along with delivery innovations such as nanoemulsions and transdermal systems-improve bioavailability and consumer confidence. Vertical integration by larger players and strategic M&A activity also professionalize supply chains and raise quality standards across the sector.

Future prospects are robust but regionally varied: pharmaceutical-grade cannabinoid therapeutics could capture high-value market segments if late-stage trials confirm efficacy, while consumer markets will mature with standardized dosing and clearer labeling. Expect consolidation as large firms pursue vertically integrated supply chains and as regulators emphasize quality control and traceability. Continued innovation in delivery platforms and clinical research will shape therapeutic adoption and long-term growth trajectories.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Cannabidiol
• Tetrahydrocannabinol
• Cannabinol
• Others

By Application

• Medicinal Use (Chronic Pain, Neurological Disorders Management, Oncology, Others)
• Non-medical Use

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores

COMPANIES PROFILED

• Mylan NV Viatris Inc, Alkem Labs, GW Pharmaceuticals plc Jazz Pharmaceuticals, Tilray Inc, Aurora Cannabis Inc, Canopy Growth Corporation, The Cronos Group, Endoca, Cannoid LLC, Medical Marijuana Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANNABINOIDS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Cannabidiol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tetrahydrocannabinol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cannabinol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANNABINOIDS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Medicinal Use (Chronic Pain, Neurological Disorders Management, Oncology, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-medical Use Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANNABINOIDS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANNABINOIDS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANNABINOIDS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Mylan N.V. (Viatris Inc.)
  • 9.2.2 Alkem Labs
  • 9.2.3 GW Pharmaceuticals Plc (Jazz Pharmaceuticals)
  • 9.2.4 Tilray Inc
  • 9.2.5 Aurora Cannabis Inc
  • 9.2.6 Canopy Growth Corporation
  • 9.2.7 The Cronos Group
  • 9.2.8 Endoca
  • 9.2.9 Cannoid LLC
  • 9.2.10 Medical Marijuana Inc